CDKN2A and pancreatic ductal adenocarcinoma: During the last decades, the genetic alterations underlying pancreatic cancer have been well characterized: 80–95% of pancreatic ductal adenocarcinomas carry activating mutations in the KRAS2 gene, and 85–98% have mutations, deletions, or hypermethylation in the CDKN2 (p16) gene.